Why are excipients important to neonates?

Current Pharmaceutical Design

Volumn 21, Issue 39, 2015, Pages 5680-5687

  Turner, Mark A ^a   Shah, Utpal ^b  

^a LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^b ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Benefit risk; Excipient; Formulation; Neonate; Prematurity; Toxicity

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; ANTIOXIDANT; BENZOIC ACID; BENZYL ALCOHOL; DILUENT; EXCIPIENT; HUMECTANT; HYDROXYBENZOIC ACID; LACTOSE; MALTITOL; METHYL PARABEN; PENETRATION ENHANCING AGENT; PLASTICIZER; POLYSORBATE; POLYSORBATE 80; PRESERVATIVE; PROPYLENE GLYCOL; SODIUM METABISULFITE; SOLVENT; SORBITOL; SWEETENING AGENT;

HUMAN; NANOTECHNOLOGY; NEWBORN; NURSE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SCIENTIST; SHELF LIFE; INFANT, NEWBORN, DISEASES;

EXCIPIENTS; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES;

EID: 84957681391     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150901110341     Document Type: Review

References (66)

1. Turner MA, Lewis S, Hawcutt DB, Field D. Prioritising neonatal medicines research: Uk medicines for children research network scoping survey. BMC Pediatr 2009; 9: 50.
2. Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC. Toxic additives in medication for preterm infants. Arch Dis Child Fetal Neonatal Ed 2009; 94: F236-40.
3. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med 2009; 10: 2569.
4. Nahata MC. Safety of "inert" additives or excipients in paediatric medicines. Arch Dis Child Fetal Neonatal Ed 2009; 94: F3923.
5. Aulton ME. Aulton's pharmaceutics: The design and manufacture of medicines. 3rd ed. Edinburgh: Churchill Livingstone, Elsevier, 2007.
6. American academy of pediatrics. "Inactive" ingredients in pharmaceutical products. Committee on drugs. Pediatrics 1985; 76: 63543.
7. "Inactive" ingredients in pharmaceutical products: Update (subject review). American academy of pediatrics committee on drugs. Pediatrics 1997; 99: 26878.
8. Pawar S, Kumar A. Issues in the formulation of drugs for oral use in children: Role of excipients. Paediatr Drugs 2002; 4: 3719.
9. FDA. Fda drug safety communication: Serious health problems seen in premature babies given kaletra lopinavir/ritonavir oral solution. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm accessed 19th May 2012.
10. CDC. Neonatal deaths associated with use of benzyl alcohol. MMWR 1982; 31: 2901.
11. CDC. Unusual syndrome with fatalities among premature infants: Association with a new intravenous vitamin e product. MMWR 1984; 33: 1989.
12. Turner MA, Duncan JC, Shah U, et al. Risk assessment of neonatal excipient exposure: Lessons from food safety and other areas. Adv Drug Deliv Rev 2014; 73: 89101.
13. Shah UU, Roberts M, Orlu Gul M, et al. Needle-free and micronee-dle drug delivery in children: A case for disease-modifying antirheumatic drugs (dmards). Int J Pharm 2011; 416: 1-11.
14. Research CfDEa. Guidance for industry: Incorporation of physicalchemical identifiers into solid oral dosage form drug products for anticounterfeiting. FDA. FDA 2011.
15. Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bunnapradist S, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: A singlecenter experience. Clin J Am Soc Nephrol 2006; 1: 844-52.
16. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665-85.
17. Goole J, Lindley DJ, Roth W, Carl SM, Amighi K, Kauffmann JM, et al. The effects of excipients on transporter mediated absorption. Int J Pharm 2010; 393: 17-31.
18. De Merlis C, Goldring J, Velagaleti R, Brock W, Osterberg R. Regulatory update: The ipec novel excipient safety evaluation procedure. Pharmaceut Tech 2009; 33.
19. EMA. Eudralex volume 3b guidelines medicinal products for human use. Safety, environment and information. Excipients in the label and package leaflet of medicinal products for human use. 2003. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003412.pdf accessed 10th June 2012.
20. Chicella M, Jansen P, Parthiban A, et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Crit Care Med 2002; 30: 2752-6.
21. Speth PA, Vree TB, Neilen NF, et al. Propylene glycol pharma-cokinetics and effects after intravenous infusion in humans. Ther Drug Monit 1987; 9: 2558.
22. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial 2007; 20: 2179.
23. Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy 2008; 28: 98491.
24. Arroliga AC, Shehab N, McCarthy K, Gonzales JP. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. Crit Care Med 2004; 32: 170914.
25. Martin G, Finberg L. Propylene glycol: A potentially toxic vehicle in liquid dosage form. J Pediatr 1970; 77: 8778.
26. Glasgow AM, Boeckx RL, Miller MK, MacDonald MG, August GP, Goodman SI. Hyperosmolality in small infants due to propylene glycol. Pediatrics 1983; 72: 3535.
27. Peleg O, Bar-Oz B, Arad I. Coma in a premature infant associated with the transdermal absorption of propylene glycol. Acta Paediatr 1998; 87: 11956.
28. MacDonald MG, Getson PR, Glasgow AM, Miller MK, Boeckx RL, Johnson EL. Propylene glycol: Increased incidence of seizures in low birth weight infants. Pediatrics 1987; 79: 622-5.
29. Yu DK, Elmquist WF, Sawchuk RJ. Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. J Pharm Sci 1985; 74: 8769.
30. De Cock RF, Knibbe CA, Kulo A, et al. Developmental pharmacokinetics of propylene glycol in preterm and term neonates. Br J Clin Pharmacol 2012.
31. Allegaert K, Vanhaesebrouck S, Kulo A, et al. Prospective assess-ment of short-term propylene glycol tolerance in neonates. Arch Dis Child 2010; 95: 10548.
32. Lau K, Swiney BS, Reeves N, Noguchi KK, Farber NB. Propylene glycol produces excessive apoptosis in the developing mouse brain, alone and in combination with phenobarbital. Pediatr Res 2012; 71: 54-62.
33. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006: CD004454.
34. Stutchfield P, Whitaker R, Russell I, Antenatal Steroids for Term Elective Caesarean Section Research T. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: Pragmatic randomised trial. BMJ 2005; 331: 662.
35. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341: 1190-6.
36. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: Role of preservatives. Pediatr Res 2001; 50: 70611.
37. Turner MA, Baines P. Which inotrope and when in neonatal and paediatric intensive care? Arch Dis Child Educ Pract Ed 2011; 96: 2 1622.
38. Smolinske SC. Review of parenteral sulfite reactions. J Toxicol Clin Toxicol 1992; 30: 597606.
39. Dani C, Vestri V, Bertini G, Pratesi S, Rubaltelli FF. Toxicity of corticosteroids and catecholamines for mice neuronal cell cultures: Role of preservatives. J Matern Fetal Neonatal Med 2007; 20: 325-333.
40. Dempsey EM, Barrington KJ. Evaluation and treatment of hypotension in the preterm infant. Clin Perinatol 2009; 36: 75-85.
41. Martone WJ, Williams WW, Mortensen ML, et al. Illness with fatalities in premature infants: Association with an intravenous vitamin e preparation, e-ferol. Pediatrics 1986; 78: 591-600.
42. EMA. Reflection paper on the use of methyland propylparaben as excipients in human medicinal products for oral use. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143139.pdf accessed 31st December 2014.
43. Mulla H, Yakkundi S, McElnay J, et al. An observational study of blood concentrations and kinetics of methyland propyl-parabens in neonates. Pharm Res 2015; 32(3): 1084-93.
44. Nellis G, Lutsar I, Varendi H, et al. Comparison of two alternative study designs in assessment of medicines utilisation in neonates. BMC Med Res Methodol 2014; 14: 89.
45. Suyagh M, Collier PS, Millership JS, et al. Metronidazole popula-tion pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011; 127: e36774.
46. Graham S, Turner MA. European study of neonatal exposure to neonates (esnee). Infant 2011; 7: 1969.
47. Yakkundi S, McElnay J, Millership J, et al. Use of dried blood spots to study excipient kinetics in neonates. Bioanalysis 2011; 3: 26913.
48. Grant JA, Bilodeau PA, Guernsey BG, Gardner FH. Unsuspected benzyl alcohol hypersensitivity. N Engl J Med 1982; 306: 108.
49. Wilson JP, Solimando DA, Edwards MS. Parenteral benzyl alcoholinduced hypersensitivity reaction. Drug Intell Clin Pharm 1986; 20: 689-91.
50. Brown WJ, Buist NRM, Gipson HTC, Huston RK, Kennaway NG. Fatal benzyl alcohol poisoning in a neonatal intensive-care unit. Lancet 1982; 1: 1250.
51. Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982; 307: 1384-8.
52. Weissman DB, Jackson SH, Heicher DA, Rockoff MA. Benzyl alcohol administration in neonates. Anesthesia Analgesia 1990; 70: 6734.
53. Nair B. Final report on the safety assessment of benzyl alcohol, benzoic acid, sodium benzoate. Int J Toxicol 2001; 20: 23-50.
54. Nagel JE, Fuscaldo JT, Fireman P. Paraben allergy. JAMA 1977;237: 15945.
55. Fisher AA. Cortaid cream dermatitis and the paraben paradox. J Am Acad Dermatol 1982; 6: 1167.
56. Loria CJ, Echeverria P, Smith AL. Effect of antibiotic formulations in serum-protein bilirubin interaction of newborn-infants. J Pediatr 1976; 89: 479-82.
57. Soni MG, Carabin IG, Burdock GA. Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food Chem Toxicol 2005; 43: 985-1015.
58. Alade SL, Brown RE, Paquet A, Jr. Polysorbate 80 and e-ferol toxicity. Pediatrics 1986; 77: 5937.
59. Balistreri WF, Farrell MK, Bove KE. Lessons from the e-ferol tragedy. Pediatrics 1986; 78: 5036.
60. Arulanantham K, Genel M. Central nervous-system toxicity associated with ingestion of propylene-glycol. J Pediatr 1978; 93: 5156.
61. Macdonald MG, Getson PR, Glasgow AM, Miller MK, Boeckx RL, Johnson EL. Propylene-glycol increased incidence of seizures in low-birth-weight infants. Pediatrics 1987; 79: 6225.
62. Allegaert K, Vanhaesebrouck S, Kulo A, et al. Prospective assessment of short-term propylene glycol tolerance in neonates. Arch Dis Child Fetal Neonatal Ed 2010; 95: 10548.
63. Jamieson DM, Guill MF, Wray BB, May JR. Metabisulfite sensitiv-ity case-report and literature-review. Ann Allergy 1985; 54: 115-221.
64. Badiga MS, Jain NK, Casanova C, Pitchumoni CS. Diarrhea in diabetics the role of sorbitol. J Am Coll Nutr 1990; 9: 57882.
65. Jain NK, Patel VP, Pitchumoni CS. Sorbitol intolerance in adults-prevalence and pathogenesis on 2 continents. J Clin Gastroenterol 1987; 9: 3179.
66. Nellis G, Metsvaht T, Varendi H, et al. Potentially harmful excipients in neonatal medicines: a pan-European observational study. ESNEE consortium. Arch Dis Child 2015; 100(7)